August 1, 2024 08:00 AM EDT

VC firm venBio secures $528M for ‘extremely selective’ fifth fund after recent IPOs, M&A exits

Kyle LaHucik

Senior Reporter

San Francisco-based investment firm venBio plans to back about a dozen new biotech startups over the coming three years with its latest fund, disclosed Thursday …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

VC firm venBio secures $528M for ‘extremely selective’ fifth fund after recent IPOs, M&A exits

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

VC firm ven­Bio se­cures $528M for ‘ex­treme­ly se­lec­tive’ fifth fund af­ter re­cent IPOs, M&A ex­its

Senior Reporter

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

VC firm venBio secures $528M for ‘extremely selective’ fifth fund after recent IPOs, M&A exits